Illumina, Inc., a leading player in the genomics industry, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 1998, Illumina has revolutionised DNA sequencing and array-based solutions, making substantial contributions to genomic research and personalised medicine. The company’s core products include advanced sequencing systems, reagents, and bioinformatics tools, which are distinguished by their high throughput and accuracy. Illumina's innovative technologies have positioned it at the forefront of the market, enabling researchers and clinicians to unlock the complexities of the genome. With numerous accolades and a robust portfolio, Illumina continues to drive advancements in genomics, supporting initiatives in healthcare, agriculture, and environmental science. Its commitment to innovation and quality has solidified its reputation as a trusted partner in the life sciences sector.
How does Illumina's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Illumina's score of 89 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Illumina, Inc. reported total greenhouse gas emissions of approximately 25950000 kg CO2e, comprising 18098000 kg CO2e from Scope 1 and 7852000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming for a 46% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. Additionally, Illumina is committed to achieving net-zero emissions across its direct operations and value chain (Scope 1, 2, and 3) by 2050. Illumina's long-term targets include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, alongside a similar 90% reduction in Scope 3 emissions, which encompass a wide range of indirect emissions from purchased goods and services, capital goods, and business travel, among others. The company also plans to increase its sourcing of renewable electricity from 0.6% in 2019 to 100% by 2030. These commitments align with the Science Based Targets initiative (SBTi) and reflect Illumina's dedication to addressing climate change and reducing its carbon footprint in the biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 12,489,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,915,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 238,110,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Illumina's Scope 3 emissions, which decreased by 19% last year and increased by approximately 2% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" being the largest emissions source at 40% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Illumina has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Illumina's sustainability data and climate commitments